Exelixis (EXEL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.4B

Revenue (quarter)

$628.7M

Revenue growth (year over year)

+10.63%

Gross profit (trailing twelve months)

$2.4B

Gross margin

96.48%

Net income (trailing twelve months)

$860.6M

Net income (quarter)

$212.1M

Net income growth (year over year)

+14.72%

Net margin

35.33%

Return on equity

44.39%

EPS (trailing twelve months)

$3.29

Book value per share

$7.41

P/E (trailing twelve months)

17.13

Price to book

8.00

Debt to assets

26.08%

Payout ratio

—

Dividend yield

—

Company profile

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

• Is Exelixis (EXEL) profitable?

  Yes. Exelixis earned $860.6M in net income over the trailing twelve months, a net margin of 35.33%.

• How much revenue does Exelixis (EXEL) make?

  Exelixis generated $2.4B in revenue over the trailing twelve months, up 10.63% year over year.

• What is EXEL's P/E ratio?

  Exelixis trades at 17.1 times trailing twelve-month earnings, on an EPS of $3.29.

• How do I buy stock in Exelixis (EXEL)?

  EXEL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.